Table 1. Baseline Characteristics of Matched Persons in the Target Trial Emulation Evaluating the Comparative Safety of the BNT162b2 and mRNA-1273 Vaccines, Veterans Health Administrationa.
| Characteristic | No. (%)b | |
|---|---|---|
| BNT162b2 recipients (n = 216 836) | mRNA-1273 recipients (n = 216 836) | |
| Age, median (IQR), y | 69.0 (60.0-74.0) | 69.0 (60.0-74.0) |
| Age group, y | ||
| 18-39 | 9335 (4) | 9335 (4) |
| 40-49 | 12 394 (6) | 12 394 (6) |
| 50-59 | 30 382 (14) | 30 382 (14) |
| 60-69 | 57 749 (27) | 57 749 (27) |
| 70-79 | 84 377 (39) | 84 377 (39) |
| ≥80 | 22 599 (10) | 22 599 (10) |
| Sex | ||
| Male | 200 908 (93) | 200 908 (93) |
| Female | 15 928 (7) | 15 928 (7) |
| Racec | ||
| Black | 43 452 (20) | 43 452 (20) |
| White | 162 603 (75) | 162 603 (75) |
| Otherd | 4202 (2) | 4202 (2) |
| Unknown | 6579 (3) | 6579 (3) |
| Ethnicityc | ||
| Hispanic | 14 791 (7) | 20 425 (9) |
| Not Hispanic | 195 911 (90) | 190 205 (88) |
| Unknown | 6134 (3) | 6206 (3) |
| Urban residence | 157 955 (73) | 157 955 (73) |
| Smoking status | ||
| Current | 71 148 (33) | 76 917 (35) |
| Former | 70 012 (32) | 65 829 (30) |
| Never | 75 676 (35) | 74 090 (34) |
| Coexisting conditions | ||
| Chronic lung diseasee | 35 616 (16) | 38 890 (18) |
| Cardiovascular diseasef | 59 153 (27) | 59 266 (27) |
| Hypertension | 137 265 (63) | 140 774 (65) |
| Diabetes | 72 895 (34) | 79 338 (37) |
| Chronic kidney disease | 20 844 (10) | 21 738 (10) |
| Liver disease | 821 (<1) | 767 (<1) |
| Cancerg | 30 490 (14) | 28 688 (13) |
| Immunocompromised stateh | 17 370 (8) | 16 764 (8) |
| Obesityi | 100 885 (47) | 101 207 (47) |
| No. of primary care visits in the past 5 y | ||
| 1-9 | 30 854 (14) | 25 291 (12) |
| 10-19 | 72 717 (34) | 70 252 (32) |
| 20-29 | 52 481 (24) | 55 013 (25) |
| ≥30 | 60 784 (28) | 66 280 (31) |
| No. of influenza vaccinations in the past 5 y | ||
| 0 | 29 863 (14) | 29 758 (14) |
| 1 or 2 | 39 133 (18) | 38 179 (18) |
| 3 or 4 | 68 123 (31) | 68 107 (31) |
| ≥5 | 79 717 (37) | 80 792 (37) |
Persons included in this target trial emulation received a first dose of BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna Inc) between January 4 and September 20, 2021. (eTable 2 in the Supplement provides detailed definitions of all baseline characteristics.)
Percentages may not total 100% because of rounding.
Race and ethnicity were reported by each person in the database.
Other included Alaska Native or American Indian, Asian, and Native Hawaiian or other Pacific Islander.
Chronic lung disease included asthma, bronchitis, and chronic obstructive pulmonary disease.
Cardiovascular disease included acute myocardial infarction, cardiomyopathy, cerebrovascular disease, coronary heart disease, heart failure, and peripheral vascular disease.
Not included here are nonmelanoma skin cancer, benign neoplasms, cancers in situ, and neoplasms of uncertain behavior.
Immunocompromised state included HIV infection, organ or tissue transplant, bone marrow biopsy, and use of any of the following medications (prescribed ≥2 times over the past year): systemic glucocorticoids, anti-inflammatory or anti-rheumatic agents in combination with glucocorticoids, immunosuppressants.
Obesity was defined as a body mass index (weight in kilograms divided by height in meters squared) of 30 or greater.